drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous gene-modified CAR T-cell therapy engineered to express a chimeric antigen receptor targeting DLL3. CAR engagement of DLL3 on tumor cells induces T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of DLL3-positive cancer cells, independent of native TCR; developed for DLL3-expressing neuroendocrine tumors such as small cell lung cancer and large cell neuroendocrine carcinoma.
nci_thesaurus_concept_id
C199628
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), with potential immunomodulating and antineoplastic activities. Upon administration, autologous anti-DLL3 CAR-T cells LB2102 recognize and induce selective toxicity in DLL3-expressing tumor cells. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer cell types. It plays a key role in embryonic development and in tumor initiation and proliferation.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous gene-modified T cells expressing a DLL3-specific chimeric antigen receptor. Binding to DLL3 on tumor cells activates the T cells, leading to expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of DLL3-positive cancer cells independent of the native TCR.
drug_name
LB2102
nct_id_drug_ref
NCT05680922